Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wing C Chan

Showing results (221-230 of 295) with videos related to

Pageof 30
Sort By:
Blood|August 14, 2015
IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphomaChao Wang, Timothy W McKeithan, Qiang Gong, et al.
Blood|October 22, 2005
Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletionsLisa M Rimsza, Robin A Roberts, Elias Campo, et al.
The American Journal of Surgical Pathology|January 26, 2011
Molecular characteristics of mantle cell lymphoma presenting with clonal plasma cell componentCarlo Visco, Sylvia Hoeller, Jeffrey T Malik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2019
L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell LymphomaJiu-Yang Zhang, Pei-Pei Zhang, Wen-Ping Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2011
BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximabJaveed Iqbal, Paul N Meyer, Lynette M Smith, et al.
Nature Communications|January 15, 2015
Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cellsCan Küçük, Bei Jiang, Xiaozhou Hu, et al.
Nature Communications|April 21, 2018
Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic targetOlli Dufva, Matti Kankainen, Tiina Kelkka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2006
BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphomaJaveed Iqbal, Vishala T Neppalli, George Wright, et al.
Nature|October 3, 2014
Loss of signalling via Gα13 in germinal centre B-cell-derived lymphomaJagan R Muppidi, Roland Schmitz, Jesse A Green, et al.
Blood|March 1, 2012
Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profilingKaren E Deffenbacher, Javeed Iqbal, Warren Sanger, et al.
Pageof 30

Showing results (221-230 of 295) with videos related to

Sort By:
Pageof 30
Blood|August 14, 2015
IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphomaChao Wang, Timothy W McKeithan, Qiang Gong, et al.
Blood|October 22, 2005
Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletionsLisa M Rimsza, Robin A Roberts, Elias Campo, et al.
The American Journal of Surgical Pathology|January 26, 2011
Molecular characteristics of mantle cell lymphoma presenting with clonal plasma cell componentCarlo Visco, Sylvia Hoeller, Jeffrey T Malik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2019
L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell LymphomaJiu-Yang Zhang, Pei-Pei Zhang, Wen-Ping Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2011
BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximabJaveed Iqbal, Paul N Meyer, Lynette M Smith, et al.
Nature Communications|January 15, 2015
Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cellsCan Küçük, Bei Jiang, Xiaozhou Hu, et al.
Nature Communications|April 21, 2018
Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic targetOlli Dufva, Matti Kankainen, Tiina Kelkka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2006
BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphomaJaveed Iqbal, Vishala T Neppalli, George Wright, et al.
Nature|October 3, 2014
Loss of signalling via Gα13 in germinal centre B-cell-derived lymphomaJagan R Muppidi, Roland Schmitz, Jesse A Green, et al.
Blood|March 1, 2012
Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profilingKaren E Deffenbacher, Javeed Iqbal, Warren Sanger, et al.
Pageof 30